Vmbook Online ordering

Osiris Therapeutics Inc

Osiris Therapeutics, Inc. is a public biotechnology company listed on the NASDAQ stock exchange under the ticker symbol OSIR. Below is some general information about the company, including its focus, earnings, and growth:

Focus:

Osiris Therapeutics, Inc. is a biotechnology company that focuses on developing and commercializing regenerative medicine products. The company's products are intended to improve the health and quality of life of patients by promoting the body's natural healing processes.

Earnings:

Osiris Therapeutics has not yet achieved sustained profitability. The company has reported net losses in each of the last five years, with the exception of a single quarter in 2018. In its most recent quarterly earnings report (Q3 2022), the company reported a net loss of $14.2 million.

Growth:

However, the company has been growing its revenue over the past few years. In its most recent quarterly earnings report, Osiris Therapeutics reported record-high revenue of $27.6 million, representing a 41% year-over-year increase. The company's revenue growth has been driven by the increasing adoption of its products, including its Grafix and Stravix products, which are used for the treatment of chronic wounds and surgical soft tissue repair, respectively.

Other informations about Osiris Therapeutics include:

* Founded in 1997, Osiris Therapeutics is headquartered in Columbia, Maryland

* The company's name comes from the ancient Egyptian god of the afterlife, Osiris, who was believed to have the power to heal

*Osiris Therapeutics' products are based on a proprietary technology called Bioactive Foam, which is designed to mimic the natural extracellular matrix and promote the body's natural healing processes.

*The company has received several regulatory approvals from the FDA for its products, including the first-ever FDA approval of a bioactive wound dressing for the treatment of diabetic foot ulcers.

Please note that the information regarding Osiris Therapeutics' financial performance is current as of the company's most recent quarterly earnings report (Q3 2022) and may have changed since then.